PDCD1 and neoplasm: For example, Belinostat has recently been shown to improve the efficacy of anti-CTLA-4 monotherapy and anti-CTLA-4 combined with anti-PD-1/PD-L1 in HCC patients, leading to complete tumor rejection (161).